Revive Therapeutics (RVVTF) Regulatory Update Archive.

April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...

And We Have Our First MEME Stock! $2.00 to $29.95.

Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention (Bloomberg) Guess we were bound to stumble across...
roland rick perry

Can This Diabetes Drug Make you Smarter?

OKAY, maybe not make you smarter, but a new study out today says it may delay the onset of dementia - so...

Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
orchestra biomed

Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation.

Orchestra BioMed™ Announces Global Strategic Partnership with Terumo Corporation for Development and Commercialization of Virtue® Sirolimus-Eluting Balloon. June 13,...
Biotech Stock Review, Novellus, Citius

Citius (CTXR) and Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19

GeoVax (GOVX) Research Reports Archive

Research Report Archive Reports from Robert LeBoyer at Noble Capital. Jeffrey Kraws and Karen Goldfarb at Crystal Research....

Adding ENDRA Life Sciences (NDRA) $0.89 to Watch List.

Another Fatty Liver Idea. This Time a Play on Detecting Fatty Liver Non-Invasively. Heads Up. Nearing Resistance at $0.89.

Latest article

We’re in Tampa for the Kentucky Derby.

GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!